Tekla Life Sciences Investors
Tekla Life Sciences Investors (HQL) is a closed-end fund focused on life sciences and healthcare equities with minimal direct political/regulatory exposure.
BusinessWhat HQL does
HQL is a closed-end investment fund that invests primarily in publicly traded life sciences and healthcare companies. Revenue derives from management fees on assets under management and investment gains. The fund itself has no direct government contracts, regulated operations, or lobbying activity.
12 months past · 3 months futureHQL activity timeline
Lifetime Government AwardsHQL federal contracts
HQL doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Congressional TradesWho in Congress is trading HQL
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
Open-market buys
Political ProfileWhere HQL sits in Washington
HQL is a passive investment vehicle with no direct regulatory exposure or government dependence. Political/regulatory moves affect underlying portfolio holdings, not HQL's operations directly.
Live signals + predictions for HQL — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades HQL
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord